In this feature by China BioInnovation, our founder and CEO Dr John LUK shares how Arbele’s source-driven innovation is redefining the development of cancer immunotherapies.Focusing on the under-explored target CDH17, Arbele is leading the way in developing first-in-class bispecific antibodies designed to treat gastrointestinal cancers, one of the world’s most pressing unmet medical needs.From uncovering the biological significance of CDH17 to advancing novel therapies like ARB202, Dr Luk's vision reflects a broader shift in China’s biotech landscape: from imitation to true innovation.

👉 Read the full Chinese article here: https://lnkd.in/gVAH-SUj